Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia-Reference-Cited by-同舟云学术

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

Published:2014-07-21 Issue:10 Volume:89 Page:947-953
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Gambacorti‐Passerini Carlo¹,Cortes Jorge E.²,Lipton Jeff H.³,Dmoszynska Anna⁴,Wong Raymond S.⁵,Rossiev Victor⁶,Pavlov Dmitri⁷,Gogat Marchant Karin⁸,Duvillié Ladan⁸,Khattry Navin⁹,Kantarjian Hagop M.²,Brümmendorf Tim H.¹⁰¹¹

Affiliation:

1. Department of Internal MedicineUniversity of Milano BicoccaMonza Italy

2. Department of LeukemiaDivision of Cancer MedicineMD Anderson Cancer CenterUniversity of TexasHouston Texas

3. Department of Hematology/Medical OncologyPrincess Margaret HospitalToronto Ontario Canada

4. Hematooncology and Bone Marrow Transplantation DepartmentMedical University of LublinLublin Poland

5. Prince of Wales HospitalThe Chinese University of Hong KongShatin Hong Kong

6. Hematology DepartmentSamara Regional Clinical HospitalSamara Russia

7. Oncology Clinical StatisticsPfizer IncNew York New York

8. Pfizer Global Research and DevelopmentParis France

9. Department of Medical OncologyTata Memorial CenterMumbai India

10. Clinic for OncologyHematologyand Stem Cell TransplantationUniversitätsklinikum AachenRWTH Aachen Aachen Germany

11. OncologyHematologyand Stem Cell TransplantationUniversitätsklinikum Hamburg‐EppendorfHamburg Germany

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.23788

Reference26 articles.

1. Structural organization of the bcr gene and its role in the Ph′ translocation

2. The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid Gene

3. Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia;Frontiers in Oncology;2024-08-26

2. Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia;Annals of Hematology;2024-07-18

3. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-05

4. Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights;Expert Opinion on Investigational Drugs;2024-04-21

5. Bosutinib Stimulates Macrophage Survival, Phagocytosis, and Intracellular Killing of Bacteria;ACS Infectious Diseases;2024-04-11